Alpha-Lactalbumin Vaccine May be ‘Exciting’ Option for Preventing/Treating TNBC

Commentary
Video
Conference|San Antonio Breast Cancer Symposium (SABCS)

More funding is necessary for additional trials investigating the potential clinical benefit of an alpha-lactalbumin vaccine for patients with high-risk operable triple-negative breast cancer and those at high risk of developing the disease, says G. Thomas Budd, MD.

In a conversation with CancerNetwork® during the 2023 San Antonio Breast Cancer Symposium (SABCS), G. Thomas Budd, MD, spoke about how the next steps for researching an alpha-lactalbumin vaccine in patients with high-risk operable triple-negative breast cancer (TNBC) and those at high risk of developing the disease may involve clinical trials investigating its efficacy across different treatment settings.

According to Budd, a medical oncologist in the Department of Hematology and Medical Oncology at the Cleveland Clinic, investigators are planning to assess the vaccine as adjuvant therapy, as patients who receive standard treatment may still be at risk for recurrence due to potential residual disease at the time of surgery. Additionally, he said that the vaccine would be further researched in patients who are at a high genetic risk of developing TNBC.

Data from a phase 1 trial presented at SABCS highlighted immune responses that met protocol specifications in 7 of 10 patients as determined with the ELISpot assay. Investigators also reported their plans to begin accrual of those with BRCA1/2 or PALB mutations who are set to undergo prophylactic mastectomy.

Transcript:

There is progress being made; we do plan to expand this [research] in two routes. One is in the adjuvant setting; patients who receive standard treatment are still at risk for recurrence because of residual disease at the time of surgery or however it may be defined in the future. They can receive this vaccination. In patients who are particularly at genetic risk for triple-negative breast cancer, hopefully, we'll be able to do a trial that demonstrates clinical benefit in that group of patients, as well.

Now, that's a tough group to study because it's not a large group. It's going to take a long time for patients to develop cancer, and of course there are surgical options at present. But it would be a very exciting approach, and we're really looking forward to trying to get funding to do these additional trials.

Reference

Johnson JM, Rhoades E, Levengood H, et al. Phase I trial of alpha-lactalbumin vaccine in high risk operable triple negative breast cancer (TNBC) and patients at high genetic risk for TNBC. Presented at the 2023 San Antonio Breast Cancer Symposium; December 5-9, 2023; San Antonio, TX; abstract PO2-17-12.

Recent Videos
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
Patients with mediastinal lymph node involved-lung cancer may benefit from chemoimmunotherapy in the neoadjuvant setting.
Stressing the importance of prompt AE disclosure before they become severe can ensure that a patient can still undergo resection with curative intent.
Thomas Marron, MD, PhD, presented a session on clinical data that established standards of care for stage II and III lung cancer treatment at CFS 2025.
Sonia Jain, PhD, stated that depatuxizumab mafodotin, ABBV-221, and ABBV-321 were 3 of the most prominent ADCs in EGFR-amplified glioblastoma.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
Computational models help researchers anticipate how ADCs may behave in later lines of development, while they are still in the early stages.
ADC payloads with high levels of potency can sometimes lead to higher levels of toxicity, which can eliminate the therapeutic window for patients with cancer.
Related Content
According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

How to Mitigate the Emotional, Logistical, and Financial Burdens of Cancer Treatment?

Tim Cortese
November 29th 2025
Article

According to Rachel Greenup, MD, MPH, some of the barriers to getting optimal treatment for breast cancer include access, insurance, and baseline understanding or knowledge.

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

What Were The Most Impactful GU Oncology Data From ESMO 2025?

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
November 6th 2025
Podcast

Experts highlight the top 5 presentations from ESMO 2025 that may have long-term clinical implications for genitourinary cancer management.

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

Will Targeting EVA1 With ADCs Eliminate Glioblastoma-Initiating Cells?

Tim Cortese
November 16th 2025
Article

According to Toru Kondo, PhD, EVA1-ADC is able to target glioblastoma-initiating cells while sparing normal cells and stem cells during treatment.

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

What Were the Key Presentations at ESMO 2025? Oncology Experts Discuss

Sara A. Hurvitz, MD;Xiuning Le, MD, PhD;Erica L. Mayer, MD, MPH
October 27th 2025
Podcast

Presenting investigators at ESMO Congress 2025 highlight findings from clinical trials assessing novel therapeutics across different disease types.

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC

Russ Conroy
November 15th 2025
Article

Data show that XCR1-positive conventional type 1 dendritic cells may play a role as mediators of response to atezolizumab in extensive-stage SCLC.

Although the study was underpowered due to a small sample size, non-significant improvements in functional and social well-being occurred with MOST-S26.

Nurse-Led Telehealth Displays Feasibility in Ovarian Cancer Follow-Up

Roman Fabbricatore
November 14th 2025
Article

Although the study was underpowered due to a small sample size, nonsignificant improvements in functional and social well-being occurred with MOST-S26.